Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
BUSINESS
ASKA Begins Japan PIII for Relugolix Combo Drug
ASKA Pharmaceutical said on December 16 that it has launched a PIII clinical trial program in Japan, dubbed LUNA, for a combination tablet of relugolix, estradiol, and norethindrone acetate, targeting uterine fibroid patients with menorrhagia. In September 2021, ASKA concluded…
To read the full story
Related Article
- ASKA Launches Japan PIII of Relugolix Combo for Endometriosis
June 26, 2025
- ASKA Extends Relugolix Combo Deal with Takeda into Endometriosis
June 3, 2024
- ASKA Begins Japan PI/II for Relugolix Combo Drug
July 21, 2023
- ASKA Earns Japan Rights to Takeda’s Relugolix Combo Drug
September 28, 2021
- Relumina Submitted for Endometriosis Use in Japan: ASKA
January 29, 2021
- Relugolix Nets Positive PIII Data in Endometriosis, ASKA Set to Seek Add’l Use in H1 2021
November 26, 2020
- ASKA Takes Over Uterine Fibroids Drug Relumina from Takeda
February 18, 2020
- Takeda Licenses Relugolix to ASKA in Women’s Health Field
June 1, 2018
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…